Efficacy outcomes by patterns of progression in patients with advanced renal cell carcinoma from the phase 3 CLEAR trial.
Journal of Clinical Oncology · 2026-05-27
Combining HC-7366 with belzutifan in patients with renal cell carcinoma to alter tumor and microenvironment: Pharmacokinetic and pharmacodynamic (PK/PD) analysis of a phase 1b study.
Journal of Clinical Oncology · 2026-05-27
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic renal cell carcinoma.
Journal of Clinical Oncology · 2026-05-27
Final analysis of lenvatinib + pembrolizumab vs. sunitinib in patients with advanced renal cell carcinoma with or without bone metastases in CLEAR
European Urology Open Science · 2025-11-01
11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis
The Oncologist · 2025-10-01
Cholinergic dysfunction in occupational manganese exposure
NeuroToxicology · 2025-09-04 · 1 citations
2603P Final analysis of lenvatinib + pembrolizumab (L+P) vs sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) with or without bone metastases in CLEAR
Annals of Oncology · 2025-09-01
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
European Urology Oncology · 2025-08-19 · 2 citations
CD70-targeted allogeneic CAR T-cell therapy for clear cell renal cell carcinoma
Expert Review of Anticancer Therapy · 2025-08-14 · 2 citations
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
Journal of Clinical Oncology · 2025-05-28 · 1 citations
The impact of obesity on survival in non-small cell lung cancer patients receiving immune checkpoint inhibitor therapy: A retrospective multi-institutional US cohort study.
Journal of Clinical Oncology · 2025-05-28
Re: Justine Panian, Caiwei Zhong, Sharon H. Choi, et al. Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.11.011
European Urology Focus · 2025-05-03
Optimizing Pharmacotherapy During Implementation of Enhanced Recovery After Surgery (ERAS) in Ambulatory Urologic Oncology Surgery: Narrative Review
Cancers · 2025-02-11 · 1 citations
Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial.
Journal of Clinical Oncology · 2025-02-10
Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC).
Journal of Clinical Oncology · 2025-02-10 · 1 citations
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
Journal of Clinical Oncology · 2025-02-10
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
The Oncologist · 2024-12-27 · 1 citations
25 Years of Progress: Key Takeaways from the 2024 IKCS
Kidney Cancer Journal · 2024-12-27
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
Annals of Oncology · 2024-12-11 · 17 citations
P179 Lenvatinib plus Pembrolizumab (L+P) vs. Sunitinib (S) in advanced Renal Cell Carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial
European Urology Open Science · 2024-11-01